



Đồng Tháp, ngày 12 tháng 06 năm 2026
Dong Thap, June 12, 2026

Số/No.: 383/2026/TIPHARCO

CÔNG BỐ THÔNG TIN BẤT THƯỜNG EXTRAORDINARY INFORMATION DISCLOSURE



Kính gửi/To: - Ủy ban Chứng khoán Nhà nước/*The State Securities Commission*

- Sở Giao dịch Chứng khoán Hà Nội/*Ha Noi Stock Exchange*

1. Tên tổ chức/*Name of organization*: Công ty Cổ phần Dược phẩm Tipharco/*Tipharco Pharmaceutical JSC*

- Mã chứng khoán/Mã thành viên/ *Stock code/ Broker code*: DTG
- Địa chỉ/*Address*: Lô 08, 09 CCN và TTCN Tân Mỹ Chánh, Phường Mỹ Phong, Tỉnh Đồng Tháp, Việt Nam / *Lot 08, 09 Tan My Chanh Industrial Park and Industrial Center, My Phong Ward, Dong Thap Province, Vietnam.*
- Điện thoại liên hệ/*Tel*: 0273.3872973 - 0913728988 Fax: 0273.3885040
- E-mail: ir@tipharco.vn

2. Nội dung thông tin công bố/*Contents of disclosure*:

Công ty Cổ phần Dược phẩm Tipharco (DTG) công bố thông tin như sau:

Tipharco Pharmaceutical JSC ("DTG") announces the following:

Ngày 12/06/2026, Hội đồng quản trị Công ty Cổ phần Dược phẩm Tipharco (DTG) đã ban hành nghị quyết số 15/2026/NQ-HĐQT-DTG về việc triển khai phương án phát hành cổ phiếu để trả cổ tức năm 2025.

On June 12, 2026, the Board of Directors of Tipharco Pharmaceutical Joint Stock Company (DTG) issued Resolution No. 15/2026/NQ-HĐQT-DTG on the implementation of the plan to issue shares to pay dividends in 2025.

3. Thông tin này đã được công bố trên trang thông tin điện tử của Công ty vào ngày 12/06/2026 tại đường dẫn: <https://tipharco.vn/quan-he-co-dong/cong-bo-thong-tin/2026>

This information was published on the company's website on On June 12, 2026, as in the link: <https://tipharco.vn/en-US/investor-relations/disclosure/2026-ENG>

Chúng tôi xin cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin đã công bố.

We hereby certify that the information provided is true and correct and we bear full responsibility to the law.

**CÔNG TY CỔ PHẦN DƯỢC PHẨM TIPHARCO/
TIPHARCO PHARMACEUTICAL JSC**

**NGƯỜI ĐẠI DIỆN THEO PHÁP LUẬT/ LEGAL
REPRESENTATIVE**



LÊ THANH TÙNG



Dong Thap, June 12, 2026

RESOLUTION

Re: Implementation of the share issuance plan for payment of 2025 dividends

THE BOARD OF DIRECTORS TIPHARCO PHARMACEUTICAL JOINT STOCK COMPANY

- Pursuant to the Enterprise Law No. 59/2020/QH14 dated June 17, 2020 of the National Assembly of the Socialist Republic of Vietnam;
- Pursuant to the Securities Law No. 54/2019/QH14 passed on November 26, 2019;
- Pursuant to Decree No. 155/2020/ND-CP dated December 31, 2020 of the Government detailing the implementation of a number of articles of the Law on Securities;
- Pursuant to the Charter of Tipharco Pharmaceutical Joint Stock Company approved by the Board of Directors on August 18, 2025 under the authorization of the General Meeting of Shareholders;
- Pursuant to the Minutes on the Consolidation of Voting Results of the Board of Directors No. 15/2026/BB-HDQT-DTG dated June 12, 2026.

RESOLVES

Article 1. Approval of the implementation of the share issuance plan for payment of the 2025 dividend in shares, as approved by the 2026 Annual General Meeting of Shareholders on March 27, 2026, with the following details:

1. Name of shares: Shares of Tipharco Pharmaceutical Joint Stock Company
2. Type of shares: Ordinary shares
3. Stock ticker symbol: DTG
4. Par value: VND 10,000 per share
5. Current charter capital: VND 96,053,180,000
6. Total number of issued shares: 9,605,318 shares
Of which:
 - o Outstanding shares: 9,605,318 shares
 - o Treasury shares: 0 shares
7. Number of shares proposed to be issued: 960,531 shares

8. Total issuance value at par value: VND 9,605,310,000
9. Issuance method: Share issuance for dividend payment
10. Eligible shareholders: Existing shareholders whose names appear on the shareholder list as of the record date. The record date shall be determined by the Board of Directors under the authorization of the General Meeting of Shareholders.
11. Issuance ratio (number of shares to be issued/outstanding shares): 10%
12. Exercise ratio: 10:1. Shareholders owning 01 share will receive 01 right to receive additional shares. For every 10 rights, the shareholder will be entitled to receive 01 new share.
13. Treatment of fractional shares (if any): The number of additional shares allocated to each shareholder shall be rounded down to the nearest whole share. Any fractional share resulting from the calculation shall be cancelled.

Example: Shareholder A owns 109 shares on the record date. Based on the exercise ratio of 10:1, Shareholder A is entitled to receive $(109/10 \times 1) = 10.90$ new shares. Pursuant to the rounding-down principle, Shareholder A will receive 10 new shares. The fractional portion of 0.90 share shall be cancelled.
14. Source of issuance: Undistributed after-tax profits as of December 31, 2025, according to the audited 2025 financial statements of Tipharco Pharmaceutical Joint Stock Company.
15. Expected implementation period: After the State Securities Commission of Vietnam confirms receipt of the complete issuance report dossier, expected in the second quarter of 2026.
16. Additional securities registration and listing registration: Upon completion of the issuance, the General Meeting of Shareholders approves and authorizes the Board of Directors to carry out procedures for additional securities registration with the Vietnam Securities Depository and Clearing Corporation (VSDC) and additional listing registration with the Hanoi Stock Exchange (HNX).
17. Approval of the change in charter capital: Approval of the amendment to the Company's Charter (with respect to charter capital) and the amendment of the Enterprise Registration Certificate with the competent state authorities after the State Securities Commission of Vietnam notifies the Company of its receipt of the report on the results of the issuance.

Article 2. Authorize the General Director of the Company to implement the share issuance plan for payment of the 2025 dividend in shares, including the following tasks:

- To carry out procedures for submitting the dossier for reporting the share issuance for dividend payment to the State Securities Commission of Vietnam and provide explanations regarding related matters upon request (if any);



- To prepare and submit to the Board of Directors for approval all documents related to the additional securities registration with the Vietnam Securities Depository and Clearing Corporation (VSDC) and the additional listing registration with the Hanoi Stock Exchange (HNX) following the notification from the State Securities Commission of Vietnam confirming receipt of the report on the results of the issuance;
- To carry out information disclosure procedures in compliance with applicable laws and regulations.

Article 3. This Resolution takes effect from the date of signing. Members of the Board of Directors, the Management Board of the Company, the Divisions, Departments, Sections and related individuals are responsible for implementing this Resolution.

Recipients:

- As Article 3
- Supervisory Board
- Filing: BOD

ON BEHALF OF THE BOARD OF DIRECTORS

CHAIRMAN



Trần Ngọc Tuan

